Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from biotechnology

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

AAP

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study,…

AAP

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Why do some high performers still end up earning less than their peers?

In the workplace, it's common to think that diligence directly translates to a fatter paycheck. Yet, the reality is more complex; some top performers find themselves earning less than their underperforming peers. This inequity not only breeds frustration but also undermines loyalty. With companies shrouding their compensation structures in mystery,…

The Economic Times

Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat

Peptide Nasal Spray: Do Nasal Spray Peptides Work?

The world of biotechnology is constantly evolving, seeking ways to make advanced treatments more accessible and less invasive. For many years, the only way to effectively administer peptides was through subcutaneous injections. However, the rise of the peptide nasal spray has changed the conversation entirely. This delivery method offers a…

inkl

PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Indian-origin biotech engineer admits exposing himself on Emirates flight to UK

An Indian-origin biotechnology engineer has admitted committing an act outraging public decency after allegedly exposing himself during an Emirates flight from Dubai to the UK, according to Daily Mail.

The Times of India

France to raise tuition fees for non-EU students from 2026-27

France will implement higher tuition fees for most non-EU students starting in the 2026-27 academic year, with bachelor's programs costing €2,895 and master's degrees €3,941 annually. This policy shift, making differentiated fees the rule and exemptions the exception, aims to reshape international student recruitment, prioritizing fields like AI and biotechnology.

The Economic Times

Anti-Aging Expert Olena Davydova on the Breakthroughs Shaping the Aesthetics Industry in 2026

The era of heavy surgical intervention is gradually giving way to the precision tools of biotechnology and artificial intelligence. We are entering a new phase in the aesthetics industry – one where the goal is no longer to correct visible flaws, but to preserve and support youthful skin at the…

inkl

Gene editing in Indonesia: can new biotechnology solve old agricultural problems?

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting its extraordinary biodiversity.

The Conversation

Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag?

Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.”...

Barchart

'Stop and re-check everything': Scientists discover 26 new bacterial species in NASA's cleanrooms

Scientists discover 26 new bacterial species in NASA cleanrooms, revealing surprisingly resilient microbes with potential uses in biotechnology and medicine.

LiveScience

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Bio-Techne Stock: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market and biotechnology industry over the past year, analysts remain strongly bullish on Bio-Techne’s longer-term prospects.

International Business Times

Colossal Biosciences Update: Lab That Brought Back Dire Wolf Buys Pet-Cloning Company

Colossal Biosciences, the Dallas-based biotechnology company known for its bold mission to resurrect extinct species such as the woolly mammoth and the dodo, announced its first-ever acquisition today: ViaGen Pets & Equine, a Texas company specializing in animal cloning and genetic preservation.

Benzinga

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Genenta Extends Collaboration With Anemocyte To Boost Off-The-Shelf Genetic Therapy Production

Genenta Science (NASDAQ:GNTA) shares traded higher in Friday's premarket after the company unveiled an expanded collaboration with biotechnology firm ANEMOCYTE.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update.

Benzinga

Sana Biotech Stock — The Next '100-Bagger'?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared on Wednesday after outspoken stock promoter Eric Jackson named it as his latest potential “100-bagger.”

Benzinga

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Benzinga

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf immunotherapy candidate, OST-HER2, for pulmonary metastatic osteosarcoma, an aggressive type of bone cancer.

Benzinga

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive week-on-week percentile gains.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Australian Research Council

Harvard Business School

50 stories

Bristol Myers Squibb

47 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.